The BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) also features a modest weight to Synageva, but the fund’s weight to that stock is enough to have the ETF trading higher by 3.8%.
BBC tracks the BioShares Biotechnology Clinical Trials Index, which is sponsored by LifeSci Index Partners, LLC.
The index excludes large pharmaceuticals companies as well as medical devices and diagnostics; life science tools; specialty pharmaceuticals, generic drugs and outsourced drug delivery; healthcare services; contract research organizations; neutraceuticals; agricultural biotechnology; animal health; diversified healthcare; food sciences; information technology; and nanotechnology firms. [More to Come for Biotech ETFs]
Companies with a lead drug candidate in a Phase 1, Phase 2 or Phase 3 trial can be included in that index.
ALPS Medical Breakthroughs ETF
